Pulmonary Drug Delivery Devices Market Report 2026

Pulmonary Drug Delivery Devices Market Overview

• Pulmonary Drug Delivery Devices market size has reached to $52.8 billion in 2025 • Expected to grow to $71.9 billion in 2030 at a compound annual growth rate (CAGR) of 6.2% • Growth Driver: Escalating Prevalence Of Respiratory Disorders Is Driving Factors Behind The Growth Of The Pulmonary Drug Delivery Devices Market • Market Trend: Innovation In Pulmonary Drug Delivery Devices • North America was the largest region in 2025.

What Is Covered Under Pulmonary Drug Delivery Devices Market?

Pulmonary drug delivery devices are inhalation devices used to deliver medications directly to the lungs. These devices allow for targeted delivery of drugs to treat respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). Pulmonary delivery also enables systemic absorption of drugs like insulin and pain medications. The main product types of pulmonary drug delivery devices included are dry powder inhalers, metered dose inhalers, and nebulizers. Dry powder inhalers are devices that deliver a measured dose of medication in the form of a fine, dry powder that the patient inhales directly into their lungs. It is provided for applications such as asthma, cystic fibrosis, chronic obstructive pulmonary disease, and others and is sold through distribution channels such as retail pharmacies, hospital pharmacies, and e-commerce.

What Is The Pulmonary Drug Delivery Devices Market Growth Forecast?

The pulmonary drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $71.9 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to increasing demand for personalized respiratory therapies, rising adoption of digital health integrated inhalers, expansion of home-based respiratory care, growing focus on non-invasive drug delivery, continued innovation in inhalation technologies. Major trends in the forecast period include increasing adoption of smart and connected inhaler devices, rising demand for targeted pulmonary drug delivery, growing use of mesh and ultrasonic nebulizers, expansion of combination drug-device products, enhanced focus on patient adherence.

Global Pulmonary Drug Delivery Devices Market Segmentation

1) By Product Type: Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers 2) By Application: Asthma, Cystic Fibrosis, Chronic Obstructive Pulmonary Disease, Other Applications 3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, E-Commerce Subsegments: 1) By Dry Powder Inhalers (DPIs): Single-Dose DPIs, Multi-Dose DPIs 2) By Metered Dose Inhalers (MDIs): CFC-Based MDIs, HFA-Based MDIs 3) By Nebulizers: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers

What Is The Driver Of The Pulmonary Drug Delivery Devices Market?

The escalating prevalence of respiratory disorders is expected to propel the growth of the pulmonary drug delivery devices market going forward. Respiratory disorders refer to diseases or conditions that affect the lungs and airways, impacting human respiration. There is an increasing prevalence of respiratory disorders due to several factors such as rising levels of air pollution, increasing smoking rates, urbanization, climate change, and the aging population. Pulmonary drug delivery devices play an important role in the treatment of respiratory disorders by allowing direct delivery of medications to the lungs. For instance, in December 2023, according to a research study published by JAMA Network Open, a medical journal by the American Medical Association, the global burden of chronic obstructive pulmonary disease (COPD) projected that the cases worldwide could reach nearly 600 million by 2050, marking a 23% increase in prevalence. Therefore, the rising prevalence of COPD is driving the growth of the pulmonary drug delivery devices industry.

Key Players In The Global Pulmonary Drug Delivery Devices Market

Major companies operating in the pulmonary drug delivery devices market are Medtronic plc, Air Liquide S.A., Becton Dickinson And Company, Koninklijke Philips N.V., Medline Industries Inc., ResMed Inc., Drägerwerk AG And Co. KGaA, Smiths Group plc, AptarGroup Inc., Chiesi Farmaceutici S.p.A., Teleflex Incorporated, Fisher And Paykel Healthcare Limited, Invacare Corporation, Vyaire Medical Inc., Inogen Inc., Drive DeVilbiss Healthcare Inc., Hovione, Hamilton Medical AG, GaleMed Corporation, Allied Healthcare Products Inc., Precision Medical Inc., Salter Labs Inc.

Global Pulmonary Drug Delivery Devices Market Trends and Insights

Major companies operating in the pulmonary drug delivery devices market are developing innovative products, such as small-volume nebulizers, to better serve customers with advanced features. A small-volume nebulizer (SVN) is a medical device used to deliver liquid medication in the form of aerosolized mist to patients with respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), or cystic fibrosis. For instance, in May 2024, Medline Industries LP, a US-based healthcare company, launched the Hudson RCI TurboMist small-volume nebulizer. This groundbreaking device is designed to deliver medication treatments quickly, in as little as three minutes. The innovative nebulizer can dispense 2.5 times more medication per minute compared to standard nebulizers, reducing treatment times by about 70%. This increase in medication delivery significantly reduces treatment times, benefiting healthcare providers by optimizing patient throughput and enhancing the patient experience by shortening the duration of therapy sessions.

What Are Latest Mergers And Acquisitions In The Pulmonary Drug Delivery Devices Market?

In January 2025, Molex LLC, a US-based electronics and manufacturing company, acquired Vectura Group Ltd. for an undisclosed amount. With this acquisition, Phillips Medisize, Molex’s CDMO arm, significantly bolsters its inhalation drug‑delivery capabilities, enabling a broader portfolio of combination products and device development. Vectura Group Limited is a UK-based pharmaceutical technology company that specializes in providing pulmonary drug delivery devices.

Regional Outlook

North America was the largest region in the pulmonary drug delivery devices market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Pulmonary Drug Delivery Devices Market?

The pulmonary drug delivery devices market consists of sales of jet nebulizers, ultrasonic wave nebulizers, and vibrating mesh nebulizers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.